Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0453Keywords:
alopecia areata, JAK inhibitors, effectivenessAbstract
Long-standing alopecia areata is a therapeutically challenging subgroup lacking robust evidence regarding Janus kinase (JAK) inhibitors. This retrospective, single-centre study evaluated the efficacy and safety of baricitinib, tofacitinib or ritlecitinib in patients with current alopecia areata episodes lasting ≥8 years, treated between February 2021 and December 2025. Among 41 screened patients, 31 met the inclusion criteria (mean age 24.6±10.1 years; mean episode duration 12.7±4.6 years). The mean baseline SALT score was 62.8±30.2, with 64.5% of patients presenting a baseline SALT score ≥50. At week 24 (n=29), 27.6% and 24.1% of patients achieved absolute SALT scores ≤20 and ≤10, respectively. Relative improvements (SALT30, SALT50 and SALT80) were observed in 48.3%, 31.0% and 24.1% of patients. Treatment discontinuation occurred in 58.1% (18/31) of patients, primarily driven by a lack of efficacy (66.7% of these discontinuations). The most frequent adverse events were folliculitis (22.6%) and acne (12.9%). While the overall therapeutic response to JAK inhibitors remains limited in long-standing alopecia areata, a subset achieves clinically meaningful hair regrowth, supporting their use as a viable treatment option.
Downloads
References
Ungar B, Renert-Yuval Y, Dlova NC, Jabbari A, King B, Mesinkovska NA, et al. Alopecia areata. Nat Rev Dis Primers 2025; 11: 77. DOI: https://doi.org/10.1038/s41572-025-00664-9
Glickman JW, Dubin C, Renert-Yuval Y, Dahabreh D, Kimmel GW, Auyeung K, et al. Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. J Am Acad Dermatol 2021; 84: 370–380. DOI: https://doi.org/10.1016/j.jaad.2020.04.138
Glickman JW, Dubin C, Dahabreh D, Han J, Del Duca E, Estrada YD, et al. An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata. Allergy 2021; 76: 3053–3065. DOI: https://doi.org/10.1111/all.14814
Deng S, Huang J, Li M, Jian J, Shi W. Complete blood collection-based systemic inflammation biomarkers as a severity biomarker in alopecia areata: A cross-sectional study. Acta Derm Venereol 2024; 104: adv40971. DOI: https://doi.org/10.2340/actadv.v104.40971
Zhou C, Yang C, Fan W, Wu J, Yang D, Jin H, et al. Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial. J Am Acad Dermatol 2026; 94: 161–171. DOI: https://doi.org/10.1016/j.jaad.2025.09.044
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 2022; 386: 1687–1699. DOI: https://doi.org/10.1056/NEJMoa2110343
King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: A randomised, double-blind, multicentre, phase 2b-3 trial. Lancet 2023; 401: 1518–1529. DOI: https://doi.org/10.1016/S0140-6736(23)00222-2
Tsianakas A, Passeron T, Magnolo N, Blume-Peytavi U, Kelly V, Day I, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial. J Am Acad Dermatol 2026; 94: 1134–1143. DOI: https://doi.org/10.1016/j.jaad.2025.11.070
Davis KL, Messenger A, Vañó-Galván S, Tran H, Napatalung L, Hanson KA, et al. Findings from the assessment of real-world disease characteristics and outcomes in alopecia areata in a global non-interventional observational cohort (ADAAGIO) study. Clin Exp Dermatol 2025; 51: 42–51. DOI: https://doi.org/10.1093/ced/llaf319
Huang J, Jian J, Li M, Ji R, Tian T, Liang X, et al. Use of ritlecitinib in patients with alopecia areata refractory to tofacitinib or baricitinib: A single-center retrospective cohort study. J Am Acad Dermatol 2026; 94: 351–353. DOI: https://doi.org/10.1016/j.jaad.2025.09.053
Huang J, Jian J, Li M, Ji R, Tian T, Liang X, et al. Real-world efficacy of ritlecitinib in treating alopecia areata across various anatomical sites: Potential rapid response predictors. J Am Acad Dermatol 2025; 93: 1236–1242. DOI: https://doi.org/10.1016/j.jaad.2025.07.008
Huang JD, Shi W. Ritlecitinib in alopecia areata: A 24-week real-world experience contrasting JAK inhibitor-naïve and JAK inhibitor-experienced patients. J Dermatol 2026.
Wang KX, Luo HG, Liu LP, Gao H, Song YY, Li D. Blockade of IL-1 family cytokines in the treatment of rheumatoid arthritis. Front Pharmacol 2025; 16. DOI: https://doi.org/10.3389/fphar.2025.1577628
Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv 2015; 1: e1500973. DOI: https://doi.org/10.1126/sciadv.1500973
Kim JE, Lee YJ, Park HR, Lee DG, Jeong KH, Kang H. The effect of JAK inhibitor on the survival, anagen re-entry, and hair follicle immune privilege restoration in human dermal papilla cells. IJMS 2020; 21: 5137. DOI: https://doi.org/10.3390/ijms21145137
Raphael I, Joern RR, Forsthuber TG. Memory CD4+ T cells in immunity and autoimmune diseases. Cells 2020; 9: 531. DOI: https://doi.org/10.3390/cells9030531
Ryan GE, Harris JE, Richmond JM. Resident memory T cells in autoimmune skin diseases. Front Immunol 2021; 12: 652191. DOI: https://doi.org/10.3389/fimmu.2021.652191
Whiting DA. Histopathologic features of alopecia areata: A new look. Arch Dermatol 2003; 139: 1555–1559. DOI: https://doi.org/10.1001/archderm.139.12.1555
Muñoz-Barba D, García-Moronta C, Haselgruber-de Francisco S, Sánchez-Díaz M, Arias-Santiago S. Effectiveness and safety of Baricitinib in alopecia areata: A prospective cohort study. J Dermatolog Treat 2025; 36: 2583877. DOI: https://doi.org/10.1080/09546634.2025.2583877
Additional Files
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
